Bio-Rad is providing its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency neutral revenue growth of approximately 0.5 to 1.5 percent and an estimated non-GAAP ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2026 on ...
Hosted on MSN
Citigroup downgrades Bio-Rad Laboratories (BIO)
Fintel reports that on April 7, 2026, Citigroup downgraded their outlook for Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral. Analyst Price Forecast Suggests 22.54% Upside As of March 27, 2026, ...
DALLAS, TX, UNITED STATES, March 19, 2026 /EINPresswire.com/ — Massive Bio today announced the launch of NexusPulse™, a real-time AI signal engine that helps ...
Bio-Rad Laboratories shares fell as the company faces margin pressure related to declining academic research funding. The stock slipped 10.6% to $261.43 Friday. Shares are down 14% over the past 12 ...
Chief Executive Officer — Norman Schwartz President and Chief Operating Officer — Jonathan DiVincenzo Executive Vice President and Chief Financial Officer — Roop Lakkaraju Yong Chung: Good afternoon, ...
HERCULES, Calif. (AP) — HERCULES, Calif. (AP) — Bio-Rad Laboratories Inc. (BIO) on Thursday reported fourth-quarter net income of $720 million, after reporting a loss in the same period a year earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results